Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Prexton Therapeutics
Biotech
Lundbeck to buy Prexton for phase 2 Parkinson’s drug
The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.
Nick Paul Taylor
Mar 16, 2018 6:52am
EuroBiotech: More Articles of Note
Jul 13, 2017 6:15am
Serono spinout raises €29M for phase 2 Parkinson’s trials
Feb 7, 2017 5:05am
Serono spinout plots path forward for Parkinson’s drug
Sep 19, 2016 9:19am
